Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DTYMK | P23919 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251685 | 0.85 | CYP1A2 (0.40) | SMN1; SMN2THRBNPC1RAB9ACYP1A2 | |
| SCHEMBL5185603 | 0.83 | P2RX3 (0.41) | P2RX3SMN1; SMN2OPRD1OPRK1GAA | |
| SCHEMBL5185597 | 0.83 | P2RX3 (0.41) | P2RX3SMN1; SMN2OPRD1OPRK1GAA | |
| SCHEMBL5185297 | 0.82 | P2RX3 (0.37) | P2RX3OPRD1OPRK1CKS1BSKP1 | |
| SCHEMBL5186451 | 0.81 | ALDH1A1 (0.37) | P2RX3SMN1; SMN2GAATHRBNPC1 | |
| SCHEMBL5187215 | 0.80 | CKS1B (0.37) | P2RX3SMN1; SMN2GAATHRBCKS1B | |
| SCHEMBL4146994 | 0.78 | NPC1 (0.36) | P2RX3SMN1; SMN2GAATHRBCKS1B | |
| SCHEMBL5186460 | 0.75 | P2RX3 (0.38) | P2RX3SMN1; SMN2GAATHRBUSP7 | |
| SCHEMBL5187025 | 0.70 | P2RX3 (0.41) | P2RX3SMN1; SMN2OPRD1OPRK1GAA | |
| SCHEMBL5251684 | 0.69 | NPC1 (0.38) | SMN1; SMN2THRBNPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | P2RX3 1177/4885SMN1; SMN2 4184/4885OPRD1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.